Although multiple therapies targeting the MET and VEGFR2 pathways have been described to have clinical benefits in HCC treatment [14, 15], it is unclear whether simultaneous inhibition of MET and VEGFR2 signaling is necessary and sufficient to inhibit HCC invasiveness and metastasis. This evidence concerns the gene MET and hepatocellular carcinoma.